



MedRhythms, Inc
183 Middle St.
Portland, Maine 04101
medrhythms.com

The Joint Standing Committee on Environment and Natural Resources

Testimony from Brian Harris, CEO, MedRhythms, Inc.

In Support Of

L.D. 1423

An Act To Amend the Extended Producer Responsibility Law for Packaging
23 April 2025

Senator Brenner, Representative Gramlich, and distinguished members of the Environment and Natural Resources Committee,

My name is Brian Harris, and I am the CEO of MedRhythms, Inc., a medical device company based in Portland, Maine. I appreciate the opportunity to testify in support of L.D. 1423, An Act To Amend the Extended Producer Responsibility Law for Packaging.

MedRhythms is committed to innovation in healthcare through the development of FDA-regulated medical devices that use music and neuroscience to improve walking and mobility in individuals with neurological injury and disease. As a Maine-based company employing Mainers and serving patients both within and beyond our state, we take seriously our responsibility to operate sustainably and in compliance with state and federal regulations.

While we support the goals of reducing packaging waste and improving recycling systems, we believe there are important changes that can be made to better support Maine businesses now and in the future. Maine is currently an outlier among the states that have enacted similar laws none of which apply the same scope to federally regulated products like medical devices and testing equipment. As a small company shipping FDA-regulated medical devices, we risk incurring serious cost under Maine's current EPR rule.

Unlike other states that exempt this type of packaging, Maine's current rule would require us to pay fees for packaging used in or shipped into the state—despite being a small market where such costs wouldn't apply elsewhere. What we pay depends on whether our packaging is deemed "readily recyclable," and under current rules, non-recyclable materials could cost up to five times more over time. Because we cannot easily change our federally regulated packaging, it's critical that the DEP and Stewardship Organization have the flexibility to adjust based on evolving data. L.D. 1423 proposes necessary and reasonable

adjustments which would better align Maine's policy with other states, and allow us to continue to provide important care by shipping our novel medical devices straight to the patients.

We urge the Committee to support L.D. 1423 and ensure Maine's EPR program works for small, innovative, and federally regulated producers like MedRhythms. With the right policy alignment, we can protect the environment and maintain our commitment to building a thriving medical technology sector in Maine.

Sincerely,

A handwritten signature in cursive script that reads "Brian Harris".

Brian Harris
Chief Executive Officer
MedRhythms, Inc.